After Vietnam, Frazier returned as a surgical resident to BCM. When funding for TAH research was restored in January 1991, Frazier became involved in further animal experiments. His innovations in the surgical treatment of severe
heart failure,
heart transplantation and MCS to be used either to substitute for or to assist the pumping action of the human heart led to the THI gaining a reputation as a global leader of transplantation and MCS programmes. Frazier performed more than 1,300 heart transplants and implanted 1,000 LVADs, exceeding the performance of any other contemporary surgeon in the world during his career.
Successful implantation of a continuous flow device In March 2011, Craig Lewis was suffering from
amyloidosis and not eligible for heart transplant due to the severity and extent of the disease, affecting also his kidney and liver. Unsuitable for a heart transplant, temporary mechanical TAH or LVAD, his small diseased heart was replaced with a continuous flow device, a pair of HeartMate II pumps, an apparatus of two pumps embraced together, following six years of research on more than fifty calves at the Texas Institute. He awoke from a coma and spent the last five weeks of his life interacting with his family. During the following year, Frazier and his colleague
William Cohn engaged with the public and professionals on their experiences. Their
TEDMED talk introduced them to Daniel Timms, who was driven to find a technological resolution and whose father had died of heart failure. Timms had an idea and sought out Frazier and Cohn in the States. The surgeons became interested, particularly with the idea that Timms's device had the potential to be a small size. Trialed in numerous calves between 2013 and 2016, some were able to run a treadmill after implantation. ==Appointments==